It’s becoming increasingly difficult for Covered Entities (CEs) to effectively manage their 340B pharmacy programs. Often times understaffed relative to the task of handling the myriad of challenges that come with managing a 340B program, they face a seemingly constant barrage of maneuvering and attacks aimed at reducing their 340B benefit. In response, many Covered Entities are evaluating new strategies to strengthen or reinvigorate their program.
We are excited to announce that Assent Consulting and Washington D.C. based-Powers Law, the leading 340B law firm, have partnered together to develop a groundbreaking compliance offering – Summitt. This program is being extended to community health centers and clinics across the nation, delivering compliance confidence.
Please join our panel of four exceptional leaders, at the forefront of 340B, as they discuss the impact of women in 340B.
Referral prescriptions can be an important additional source of 340B funding for covered entities (CEs). However, it wasn’t until recently that referral prescriptions moved out of the “grey area” of 340B and into the mainstream. Just three years ago, most CEs avoided this area due to operational and compliance concerns. Today, many CEs have already added referral prescription capture to their 340B programs or are actively evaluating solutions.
Acentrus Specialty hosted its first Acentrus Specialty Conference on January 12-13, 2021, which brought together pharmacists, manufacturers, and suppliers to examine the challenges, opportunities, and best practices in advancing health system specialty pharmacy practice. A pharmacy paradigm shift is under way, as Integrated Delivery Networks (IDNs) are partnering to grow their specialty pharmacy operations.